Gonadotropin withdrawal induces changes in gene expression in all three major cell types of the testis.
Introduction
The molecular mechanisms by which the gonadotropins LH and FSH support the testicular production of steroids and gametes in humans are poorly understood. However, such knowledge is important for improved understanding of the regulation of testicular function and for the development of safe and efficacious contraceptive methods.
LH receptors are present on Leydig cells where they control steroid biosynthesis and thus the production of testosterone. Testosterone and FSH receptors are found on Sertoli and peritubular cells but there are no receptors for any of these hormones on germ cells (Themmen and Huhtaniemi, 2000; Collins et al., 2003) with the exception of mature human sperm which have recently been shown to have functional androgen receptors (Aquila et al., 2007) . This indicates that the effects of these hormones on immature germ cells must be indirect as all are required for quantitatively normal spermatogenesis (Matsumoto et al., 1983; Matsumoto et al., 1984) .
Gonadotropin suppression results in suppression to azoospermia in most but not all men (Anderson and Baird, 2002) . Suppression can be achieved by the administration of testosterone alone or with a GnRH antagonist, but the addition of a progestogen increases spermatogenic suppression and is currently the most promising approach towards a hormonal male contraceptive (Nieschlag et al., 2003) . It has been suggested that the degree of spermatogenic suppression in some progestogen regimens is greater than can be accounted for by gonadotropin suppression, which may indicate that progestogens act directly on the testis (McLachlan et al., 2004) . Both nuclear and membrane progesterone receptors have been found on spermatozoa, Sertoli and some Leydig cells in the human testis (Shah et al., 2005) and progestogens have direct inhibitory effects on Leydig cell function in a murine cell line (El-Hefnawy et al., 2000) . We have recently provided direct evidence for a progestogenic effect on 5α-reductase expression in the testis (Walton et al., 2006) which may reduce the amplifying effect of conversion of testosterone to dihydrotestosterone and thus contribute to greater suppression of spermatogenesis.
In order to identify a more comprehensive picture of the effects in humans of suppression of gonadotropins by administration of a GnRH antagonist and of the addition of progestogen, we have now performed microarray analysis of gene expression on testis biopsies and show that the pharmacological effects are focused on a select number of pathway-specific genes indicating stringent regulation of testicular gene expression.
Methods

Study design, drug treatment and testis biopsy
The study protocol has been described in detail previously (Walton et al., 2006) . In brief, 30 men (mean age 38 years) requesting vasectomy were recruited and written informed consent obtained. The study had ethical approval from the Lothian Regional Ethics Committee. Pre-treatment investigations demonstrated all had normal semen analysis and reproductive hormone concentrations. Subjects were randomised using sealed envelopes into 3 groups. Controls received no drug treatment before testis biopsy. A second group received cetrorelix 3mg s.c. (Cetrotide®, Serono Europe Ltd, London, UK) twice each week and testosterone enanthate 200mg i.m. (Cambridge Laboratories, Wallsend, UK) repeated after 2 weeks; the third group took the progestogen desogestrel 300μg orally (Cerazette®, 4 x 75μg, Organon NV, Oss, The Netherlands) each day for the 28-day duration of the treatment period in additional to the other agents (CT and CTD groups respectively).
One subject withdrew for personal reasons. After 4 weeks of drug treatment, further blood and semen samples were analysed and testis biopsies carried out on the remaining 29 men under local anaesthetic at the time of vasectomy using a 14-gauge needle (Tru-Cut®, Allegiance Healthcare Corporation, USA).
Tissue samples were immediately frozen and stored at -80 0 C.
RNA Samples
Total RNA was extracted from testis biopsies as described (Walton et al., 2006) . Quality was confirmed on RNA 6000 Nanochips in the Agilent 2100 Bioanalyzer. Only very high quality RNA (RIN>7.5) preparations were considered for microarray screening. Five RNA samples from each of the control, CT and CTD groups were used for screening the microarrays, along with the 5 "non-suppressors" from the treatment groups (3 CT, 2 CTD) who did not show a reduction in sperm concentrations to below the normal range (Walton et al., 2006) .
Microarray Hybridisation and Analysis
Affymetrix Human genome U133 plus 2.0 microarrays, containing 54675 probes representing approximately 39000 genes, were hybridised to 15 μg fragmented biotin-labeled cRNA prepared from each RNA and spiked with eukaryotic hybridisation control in a volume of 200μl for 16 h. After hybridisation, the arrays were washed on the Genechip Fluidics Station 450 and scanned using the Genechip Scanner 3000 all according to the manufacture's protocols (Affymetrix UK Ltd, High
Wycombe, UK).
Raw microarray data were processed and analysed with R 2.1.1 statistical environment (http://www.Rproject.org) and Bioconductor 1.6 microarray libraries (Gentleman et al., 2004) . Numerical quality control steps were applied to each of the 20 samples. Arrays were normalised and converted to probelevel data using Robust Multi-Array Average (RMA, Irizarry et al., 2003) . In order to reduce statistical multiple testing and algorithmic problems in downstream analysis, a non-specific filter to remove genes expressed at low levels (signal < log2 (100)) in all of the samples was applied. This non-specific filter is set quite stringently to remove low signal genes and thus reduce the number of false positives given the relatively low sample size in each group. It reduces the number of genes available for comparison from about 19000 which pass the basic Affymetrix quality criteria (MAS5 Present/Marginal/Absent calls) to 5824 after non-specific filtering but gives more reliable results.
To identify candidate genes that change in response to the various treatments, differential expression (by at least 2-fold) and its statistical significance for each gene was calculated based on an empirical Bayes test (Smyth, 2004) , which is robust for small sample sizes. Analysis involved 3 different stages. Stage 1 testing compared gene expression between controls and each of the treatment groups (nControl=5, nCT=7, nCTD=7), as well as between the two treatment groups. Stage 2 testing repeated these comparisons with "non-suppressed" patients removed (nCT-ns=4, nCTD-ns=5). Stage 3 testing explicitly compared all "non-suppressed" patients (n(ns)=5) to the "suppressed" patients in each of the two treatment groups (nCT(s)=4, nCTD(s)=5). A reduction in the potential number of false positive results was achieved by correcting the significance test P-values in relation to the number of genes tested simultaneously (n=5824) (Benjamini and Yekutieli, 2005) .
Functional characterization of significantly expressed transcripts was performed using the resource tool "DAVID" from the National Institute for Allergy and Infectious Diseases (NIAID) (http://niaid.abcc.ncifcrf.gov/). DAVID examines the overrepresentation of gene ontology pathways within a set of transcripts and provides statistical evaluation of the presence of these transcripts. Statistical significance was based on a P-value of 0.05 or less. Analyses were made using the filtered set of 5824 genes.
Clustering analysis was next performed: by tagging the statistically significant genes and then isolating genes which cluster alongside them, it is possible to identify additional genes which are potentially coregulated. These may be missed by statistical group means testing but may be biologically interesting.
This was carried out with the open-source Java application Biolayout Express 3D (Goldovsky et al., 2005; Freeman et al., 2007) which is specifically designed for the construction, visualisation, clustering and analysis of transcription networks generated from microarray datasets. The networks created by the software consist of nodes (representing transcripts) which are connected by edges (which represent similarities in expression profiles across multiple conditions). The analysis was performed on the entire RMA normalised data set (54675 gene probes) from all of the sample arrays (n=20). The statistically significant genes in the original differential expression list were flagged, allowing them to be identified in the network graphs produced in Biolayout Express
3D
. Clustering graphs where then produced using a
Pearson threshold of 0.9 and a Markov Clustering Algorithm (MCL) inflation of 1.7 and those containing the flagged gene set identified. Additional co-regulated genes were thus identified and the extended probe lists from these clusters were then analysed with DAVID Pathway analysis software to identify enrichment of gene ontologies within the lists.
Finally, an additional non-parametric means of verification of the data was obtained by assessing differential gene expression of the original data using the independent Rank Product method (Breitling et al., 2004) . Briefly this technique ranks each gene in each of the replicate samples, the product of these ranks is then calculated. Statistical significance is assigned by comparing the observed rank product value against a bootstrapped Null Distribution of rank product values for each gene and the genes are sorted with the highest ranking genes being placed at the top of the list. .
Real-time Quantitative RT-PCR
First strand cDNA (+/-Reverse Transcriptase) prepared from all testis biopsy samples as described previously (Walton et al., 2006) was utilised for confirmation of array results by real-time quantitative RT-PCR. This was performed using the Lightcycler (Roche Diagnostics, East Sussex, UK). Reverse transcribed RNA samples were diluted 1/10 in nuclease-free water (Promega Ltd., Southampton, UK).
1µl diluted first strand cDNA was added to a final volume of 10 µl containing 50µg/ml BSA and 0.5 µM each of forward and reverse primer in 1 x Platinum SYBR Green qPCR SuperMix UDG (Invitrogen, Paisley, UK) in duplicate. Primers (Table 1) were either previously published or designed using online Primer3 software. mRNA concentration was calculated relative to that of the ribosomal protein RPL32.
RPL32 had previously proved to be the most consistent reference gene for these samples (Walton et al., 2006) .
Results of these analyses are presented as mean ± SEM. Treatment effects on gene expression data were initially compared by ANOVA. Where ANOVA suggested significant treatment group effects, this was further investigated by unpaired t tests with cube-root transformation to normalise the distribution. For all comparisons a P-value of <0.05 was considered significant.
Results
Spermatogenic suppression
Marked and similar suppression of spermatogenesis was seen in both treated groups although there was some inter-individual heterogeneity. Median sperm concentration fell to 0.6 x10 6 /ml in the CT group and to 2.6 x10 6 /ml in the CTD group (both P<0.01 vs. pre-treatment). However 3 subjects in the CT group and 2 in the CTD group maintained sperm concentrations in the normal range (>20 x10 6 /ml) at day 28, whereas sperm concentrations were less than 5 x10 6 /ml in all others. This allowed classification of 14 men as 'suppressors' and 5 as 'non-suppressors' (Walton et al., 2006) .
Preliminary array analysis
Five high quality RNA samples were chosen from each treatment group (control, CT and CTD ) along with RNA from each of the 5 'non-suppressors' for analysis on Affymetrix microarrays, thus a total of 20 samples were analysed. Following data processing and analysis, 1 sample from the CT group showed a poor RNA digestion plot and was excluded from further analysis. After data quality control, normalisation and non-specific filtering, 5824 probes -10.6% from the total of 54675 probes on the chip -showed expression of >log2(100) for at least 1 sample.
These 5824 probes (Supplementary Table 1 , available online at www.andrologyjournal.org) represent the predominant genes expressed in the adult human testis. Assignment of Gene Ontology (GO) pathways to each gene allowed them to be grouped and for biological processes statistically over-represented in the testis to be identified (Table 2) . Not surprisingly, these included genes involved in sexual reproduction, with cell death genes also highly represented. Other significant processes were growth regulation, enzyme regulation, cell physiology and metabolism.
A striking finding on initial analysis was that inter-individual variability was remarkably low. The median coefficient of variance within each group was 6.5% for controls, 6.7% for the CT group and 7.8% for the CTD group with 95 th percentile of CV% values of 14%, 12.9% and 15.2% respectively. The average correlation between samples in a group was >0.99 for control and CT groups and >0.98 for the CTD group. This level of variation is in marked contrast to other tissue biopsy types which show far greater variability (Whitney et al., 2003; Radich et al., 2004; Critchley et al., 2006; and unpublished observations) and supports the biological significance of the array data.
Analysis of the effect of gonadotropin suppression
Expression of very few genes was altered between the groups, as demonstrated by volcano plots ( Fig.1a and b). Few genes showed significant 2-fold or greater differences between controls and treatment groups although a greater number of genes showed significant differences that were less than 2-fold. No significant differences were identified between CT and CTD treatment groups at this stage ( Fig.1c) .
Stage 1 testing identified only 15 genes which showed at least a 2-fold change in gene expression between controls and one or both of the treatment groups (Fig.2) . Many of these genes are known to be involved in steroidogenesis and cholesterol metabolism (CYP17A1, DHCR24, HSD17B6, STAR, CYP11A1, HMGCS2). One gene, CYP17A1, had already been shown to be down-regulated in the CT and CTD groups by qRT-PCR (Walton et al., 2006) . However, other genes in that study showing changes in expression level in the treatment groups were not highlighted by this screen due to sensitivity differences between the two methods, as discussed below. Nevertheless, several novel genes (INSL3, SYCP1, WISP2, CST9L, FLJ35767 and DDR1) were identified for which the function or site of expression suggested that they might be of particular interest for further examination. The array analysis indicated approximately 10-fold down-regulation of INSL3 between controls and treated samples, with 2-3 fold changes for FLJ35767, SYCP1 (only in the CTD group), WISP2 and CST9L (only in the CT group), and about 2-fold up-regulation of DDR1 in both groups. Quantitative RT-PCR analysis (Fig.3A) on the complete set of biopsy RNA samples (Walton et al., 2006) showed degrees of down-regulation similar to those in the arrays for INSL3 (P<0.001), SYCP1 (P<0.01), WISP2 (P<0.05) and FLJ35767 (P<0.01) in both treatment groups. FLJ35767 was the only gene identified for which expression was lower in the CTD group than in the CT group (P=0.03). INSL3 was lower in suppressors than non-suppressors in the CT group (18.7±3.5% vs 36.5±0.6% relative to RPL32, p<0.012) but not in the CTD group. Based on qRT-PCR, CST9L expression was actually increased to a small but significant extent in both treatment groups compared to controls while DDR1 showed no significant change.
The remaining genes identified as down-regulated from this first stage of testing were CT45-1 and 3, closely related cancer-testis antigens; PAPSS, 3'-phosphoadenosine 5'-phosphosulfate synthase 2 which is involved in purine metabolism and DPEP3 (MDB3), a testis-specific dipeptidase involved in glutathione degradation (Habib et al., 2003) .
Analysis by degree of spermatogenic suppression
Stage 2 testing (excluding men showing poor suppression of spermatogenesis) identified a further 5 genes (SC4MOL, GSTA2, CHGA, PRPS2, and CYB5, Table 3 , upper section) which were significantly down-regulated at least 2-fold in the CT group relative to controls. Similar down-regulation in the CTD group did not reach significance but there was no difference between CT and CTD groups.
No statistically significant differences were identified by the stage 3 test comparing sperm 'nonsuppressors' and 'suppressors' in the two treatment groups. However, 4 genes (PROK1, PGRMC1, APOE, RHOB, Table 3 , lower section) which had shown small (<2-fold) but statistically significant reduction in expression between controls and the CT group, but not the CTD group, after stage 1 testing also showed slightly higher expression in CTD sperm 'suppressed' samples compared to 'nonsuppressed' samples. Although these array-based differences were not significant, this potentially intriguing effect of added progestogen was investigated further by qRT-PCR analysis on the full set of 29 samples (Fig. 3B ). This demonstrated that PROK1, PGRMC1, and RHOB in fact showed significant 2-3 fold down-regulation between control and all treated samples from both groups, with no difference between non-suppressors and suppressors in either. APOE showed a 2-3 fold down-regulation which was only significant in the CT group (P=0.04), as in the arrays, but did not differ significantly between nonsuppressors and suppressors within the CTD group (P=0.8).
Given the dominance of GnRH suppression over progestogen mediated effects and the absence of differences between the CT and CTD groups in terms of global gene expression, a final round of testing compared control samples versus pooled CT and CTD groups. This identified no additional genes.
TAF4B is a germ cell specific transcription factor which has recently been shown in the ovary to regulate expression of a number of genes including INHA and RHOB (Geles et al., 2006) . Since both INHA (Walton et al., 2006) and RHOB (this study) were down-regulated in the treatment groups, it seemed a likely possibility that this might occur through regulation of TAF4B. Although not identified in the array analysis (it neither passed the non-specific filter nor showed an at least 2-fold change between groups), using qRT-PCR (Fig.3C) we demonstrated a small (30%) but significant reduction in TAF4B expression in both treatment groups.
Clustering Analysis
Clustering analysis was also performed on the entire RMA-normalised dataset using Biolayout Express 3D (Goldovsky et al., 2005; Freeman et al, 2007) . The networks produced by the software consist of nodes which represent individual transcripts connected by edges representing similarities in their expression profiles across multiple conditions. This approach allows the rapid identification of biological relationships that may be missed by conventional analysis techniques, i.e. statistical two-sample tests.
Several small cluster graphs and one major graph of genes which contained 19 out of the 20 probes from the original gene list were produced. Following clustering with MCL, the statistical hits (x 20 probes) separated out into 2 distinct clusters. The first cluster (Cluster 1, showed enrichment for genes involved in 'steroid, lipid and cholesterol biosynthesis/metabolism' ( Table   7) .
Rank Product Analysis
Finally, as an independent means of assessing differential gene expression, the original data were subjected to Rank Product Analysis (Breitling et al., 2004) . The gene list generated by this method (data not shown) was very similar to the expanded gene lists generated from Biolayout Express 3D , indicating that the additional genes identified are likely to have some biological significance. A summary of the notable genes identified in the screens, along with potential functions and sites of expression within the testis is provided in Table 8 .
Discussion
Microarray comparisons between biopsies of men treated with GnRH antagonist +/-progestogen and controls yielded a remarkably small subset of genes which were altered between the three groups, with most reflecting changes in Leydig cells. Cluster analysis suggests that the genes fall into two distinct groups -one set of genes involved in gametogenesis and spermatogenesis, and the other involved in steroid and cholesterol biosynthesis/metabolism. The significance of the biological functions in the original gene lists are increased in the expanded lists generated after cluster analysis suggesting a genuine biological relationship between them. Further confirmation of the biological significance of these expanded gene lists comes from the very similar results obtained using the alternative Rank Product method (Breitling et al., 2004) .
The striking homogeneity both between individuals and between treatment groups may paradoxically reflect heterogeneity within the testis. Marked histological variation in spermatogenic activity between nearby tubules has been observed in men treated with similar regimens to those here (McLachlan et al., 2002) . Thus the biopsies will contain tubules with varying suppression which are then averaged during processing, potentially leading to smaller apparent changes in gene expression within the tubule compartments. Sertoli cell and spermatogonial genes are also likely to be highly under-represented in RNA from total testis biopsies since the major cellular component will be post-meiotic germ cells, thus reducing the sensitivity to changes in these cells. This is a limitation of the use of whole testis biopsies.
Meanwhile, more consistent changes will be observed in genes confined to Leydig cells and thus will be more pronounced. In addition, some genes may be expressed in many cell types but only regulated by gonadotrophins in, for example, Leydig cells. This will lead to a robust expression level that partially masks changes in one cell type between control and treated samples.
Previously (Walton et al., 2006) , we identified a small number of genes by qRT-PCR in which expression was reduced in at least one of the treatment groups, but only 1 of these (CYP17A1) overlapped with the genes identified here by array analysis. Probes for all of the other genes were present on the arrays but in a number of cases (SRD5A1, HSD3B2, MAGEA4) their expression level was below the filtering threshold and therefore they were excluded from the analysis. The remaining genes (INHA, PEPP-2 and ACRBP)
were present in the filtered gene set but did not show a >2-fold change in hybridisation and did not show statistical significance better then p<=0.05. While a very useful tool, it is well known that arrays are less sensitive than qRT-PCR in detecting small changes in gene expression, especially with modest numbers of clinical samples, and many of the changes we observed by qRT-PCR were only around 2-fold and therefore close to the cut-off level. In addition, these genes are expressed in the tubule compartment and so inter-tubule variation in suppression as mentioned above may have had an effect here.
Overall, the most significant changes identified were in expression of genes involved in cholesterol biosynthesis/metabolism and steroidogenesis which are directly sensitive to the concentration of LH acting on Leydig cells. Also within this group, SC4MOL which is involved in cholesterol biosynthesis (Li and Kaplan, 1996) , and CYB5, the product of which binds and allosterically modulates CYP17 in Leydig cells (Dharia et al., 2004) showed small changes in expression. APOE has many functions but its role in cholesterol homeostasis (Levi et al., 2005) may also be relevant in this context. The observation that APOE was significantly down-regulated in the CT but not CTD groups suggests that progestogens, known to regulate Leydig cell steroidogenesis (El-Hefnawy et al., 2000) , may impact on its expression.
The only other gene observed to show a dramatic reduction in expression was INSL3, which is also expressed in Leydig cells. Serum concentrations were not affected by hCG administration to normal men (Bay et al., 2005) , however LH suppression resulted in reduced INSL3 concentrations (Bay et al., 2006) .
INSL3 is known to be induced by the transcription factor NR4A1 (Nur 77) (Robert et al., 2006) which is expressed at low levels but is rapidly and robustly induced by LH and cAMP analogs and is thought to mediate the dynamic expression of INSL3 in response to LH (Robert et al., 2006) . The steroidogenic enzyme genes 3BHSD2, CYP17A1 and STAR are also activated by NR4A1 (Zhang and Mellon, 1997; Martin and Tremblay, 2005) . Thus reduced LH will lead to reduced NR4A1 (expression of which was below the threshold to detect changes in the array) which will produce lower levels of 3BHSD2, CYP17A1, STAR and INSL3 all of which we have observed here and/or reported previously (Walton et al., 2006) . Recently, it has been demonstrated that serum INSL3 concentrations are higher in nonsuppressors than suppressors on male contraceptive regimens (Amory et al., 2007) . In this context, it is notable that we also observed higher levels of INSL3 transcripts in non-suppressors compared to suppressors in the CT group (but not the CTD group).
The receptor for INSL3, LGR8, is expressed in both Leydig cells and in meiotic and post-meiotic germ cells but not in Sertoli or peritubular cells (Kawamura et al., 2004; Anand-Ivell et al., 2006) . Insl3 knockout mice show cryptorchidism and Insl3 regulates apoptosis in germ cells in both male and female mice (Kawamura et al., 2004) . As germ cells do not express gonadotropin receptors, germ cell genes cannot be directly regulated by gonadotrophins. INSL3 may therefore provide a link between Leydig cells and spermatogenesis, which may contribute to the changes in gene expression levels observed here in the germ cell compartment such as for SYCP1, a gene essential for chromosomal synapsis at prophase I of meiosis and detected in the Stage 1 screen, as well as SYCP3, DMC1, DAZ1,MSH5, TEX11, TEX14, TEX101 and HORMAD1 and 2 which were identified from the cluster analysis. We detected previously (Walton et al., 2006) reduced expression of ACRBP, a spermatocyte-specific marker in the CTD and "suppressor" groups and of MAGEA4, which is present in spermatogonia and primary spermatocytes, in the "suppressor" group. In contrast, expression of PRM1, a post-meiotic germ cell marker, remained unchanged. Together with these new early meiotic genes, this further implicates an effect of the treatments on early stages of spermatogenesis. What is currently less clear is whether the reduced expression of germ cell markers after treatment is due to small changes in gene expression within germ cells or loss of a percentage of early germ cells, as has been observed at the histological level under similar regimens (McLachlan et al., 2002) . Both would yield the same result. This could be resolved by histochemical analysis of biopsies for these gene products but insufficient material was available to us for this.
Further genes known to be expressed by Leydig cells and showing significant down regulation during gonadotropin suppression were CHGA and PROK1. Expression of CHGA correlates with LH levels (Ortega et al., 2004) . However, in the bovine testis, CHGA expression is also high in spermatogonia of CHGA in the treated men may also reflect suppression of spermatogenesis. PROK1, a prokineticin, encodes EG-VEGF which is expressed in Leydig cells and is thought to be involved in the integrity and proliferation of blood vessels in the testis (Samson et al., 2004) . Knock-out in mice of one of its receptors, Pkr2, causes severe atrophy of the reproductive system (Matsumoto et al., 2006) , an effect partly due to low concentrations of gonadotropins associated with lack of GnRH but also thought to have a direct testicular component. In the ovary, expression of PROK1 positively correlates with granulosa cell steroidogenesis (Kisliouk et al., 2003) .
PGRMC1 (HPR6) encodes a component of the putative membrane progesterone receptor and is able to activate cytochrome P450 enzymes (Crudden et al., 2005) . A reduction in its expression may therefore contribute to reduce expression of such enzymes. The array data suggested suppression in the CT but not CTD groups, but qRT-PCR analysis demonstrated similar suppression in both groups.
While small changes in expression could simply be due to loss of a proportion of some germ cell types, alteration in the dynamics of Sertoli cell -germ cell adherens junctions was suggested by changes in expression of RHOB, a member of the RAS gene family (Lui et al., 2003) . The breakdown of adherens junctions is necessary for germ cells to detach from Sertoli cells at spermiation, suggesting the possibility that reduction in expression of RHOB and its associated regulatory transcription factor TAF4B (Geles et al., 2006) may block this process as a mechanism for the failure of spermiation observed during male contraceptive regimens . RhoB expression at adherens junctions is increased by 1-(2, 4-dichlorobenzyl)-indazole-3-carbohydrazide (adjudin), which interferes with adhesion of spermatids and spermatocytes to Sertoli cells and hence their maturation and is a promising approach to reversible male contraception (Lui et al., 2003; Mruk et al., 2006) . The WNT1 pathway is also involved in the regulation of adherens junctions (Wechezak and Coan, 2003) and WISP2, a component of the WNT1 signalling pathway (Banerjee et al., 2003) , was reduced in both treatment groups. A further potential gene associated with regulation of adherens junctions and the only gene identified as increased in both treatment groups is CST9L, a cysteine protease inhibitor (Siu and Cheng, 2004) .
Of the remaining genes whose levels were observed to fall in the treated groups, PAPSS and PRPS2 are genes involved in nucleotide metabolism and GSTA2 and DPEP3 have a function in glutathione metabolism. Both of these biological processes were found to be statistically over-represented in the testis when higher level GO and KEGG analysis was performed on the expressed gene set (P=0.03 and 0.05 respectively), indicating their importance in the testis.
Very few genes were differentially suppressed between the two treatment groups. Some were only significantly different from controls in one group (e.g. CT group: APOE, HSD17B6, STAR, PRPS2, GSTA2; CTD group: SYCP1, DPEP3) but qPCR analysis showed significantly different expression in CT vs. CTD in only one gene, FLJ35767. This is an EST isolated from a human testis library whose predicted coding sequence shows similarity to two mouse proteins, Tex19 and a hypothetical protein.
Tex19 is expressed in spermatogonia (Wang et al., 2001) . The finding that FLJ35767 is further downregulated by desogestrel than by GnRH antagonist and testosterone alone suggests a progestogenic effect, as we have previously reported for SRD5A1 (Walton et al., 2006) . This provides further evidence for direct progestogenic effects on the testis. However it is striking that only one such gene was identified in this study indicating that this may be of limited biological significance. The absence of any significant differences between suppressors and non-suppressors (other than for INSL3) within the treatment groups was disappointing. Given that the data were so tight between individuals it seems likely that an array approach will require more refined tissue sampling to be of value in this key issue.
In summary, this study identifies the 10% of genes most highly expressed in the human testis. Volcano plots of the filtered gene set representing both differential expression and its statistical significance. The X axis shows differential expression between two groups, and the Y axis the statistical significance. Genes above the lower horizontal dotted line have an adjusted P-value ≤0.05. Genes above the upper horizontal dotted line have an adjusted P-value ≤0.01. There were no significant differences in expression between CT and CTD groups. In comparison with control samples, only a small number of genes showed differential expression and statistical significance.
Figure 2
Graphical representation of log2 fold changes in expression in the CT (black bars) and CTD (grey bars) groups relative to controls for each gene identified in the Stage 1 test of array data. Bars below the line represent fold decreases while those above the line represent increases in expression. . * P<0.05, **P<0.01, *** P<0.001 vs. controls
Figure 3
Quantitative RT-PCR analysis of expression of (A) significant genes of interest identified after stage 1 testing, (B) genes identified as showing notable expression changes between suppressor (CTsupp. and CTDsupp.) and non-suppressor (ns., light grey bars) sub-groups after stage 3 testing and (C) TAF4B, an associated transcription factor of RHOB, in controls (dark grey bars) and men in CT (black bars) and CTD groups (white bars), mean ±sem. Gene expression is relative to RPL32. * P<0.05, **P<0.01, *** P<0.001 vs. controls, ‡ P<0.05 CTD vs. CT group. n=7-10 per group except non-suppressors (n=5). % is out of a total number of 59 separate genes in the cluster. Major relevant pathways and genes are marked in Bold. 
